Figma Shares Indicated To Open $105/$110
Investing.com - UBS raised its price target on Penumbra (NYSE:PEN) to $335.00 from $330.00 on Wednesday, while maintaining a Buy rating on the medical device company’s stock. According to InvestingPro data, Penumbra currently commands a market capitalization of $9.86 billion and trades at relatively high earnings multiples.
The price target adjustment follows Penumbra’s quarterly results, which showed sales of $339.5 million, representing 13.4% year-over-year growth and exceeding Street estimates by 3.7%.
Penumbra also reported earnings per share of $0.86, a 34.3% year-over-year increase that came in 4.7% above analyst expectations.
UBS cited several factors supporting its continued Buy rating, including clear visibility into double-digit top and bottom-line growth prospects for the company.
The firm also highlighted Penumbra’s ongoing market share gains and penetration runway in the U.S. venous thromboembolism (VTE) market, along with the company’s relatively low exposure to tariffs.
In other recent news, Penumbra Inc . reported its second-quarter 2025 earnings, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of $0.86, exceeding the anticipated $0.83. Additionally, Penumbra’s revenue reached $339.5 million, surpassing the forecasted $327.77 million. These results highlight the company’s strong financial performance in the recent quarter. Despite the positive earnings report, Penumbra’s stock experienced a decline, which may be attributed to broader market trends or profit-taking, though this is not confirmed. Investors may find these financial results noteworthy as they reflect the company’s ability to exceed market expectations. The focus remains on how Penumbra will continue to perform in upcoming quarters.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.